Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo

SHEN Ye-hua~1; FU Jie~1; LIU Lu-ming~

doi:10.13422/j.cnki.syfjx.2010.02.047

您当前的位置：

首页 >

文章列表页 >

Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo

更新时间：2024-09-23

- Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 16, Issue 2, Pages: 84-86(2010)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院
  2. 复旦大学上海医学院
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2010.02.047
  CLC： R735.9
- Published：2010
- 稿件说明：
移动端阅览
[1]沈晔华,傅洁,刘鲁明,沈瑾,李栋良.清胰化积方联合吉西他滨对人胰腺癌SW1990移植瘤细胞凋亡及Bcl-2蛋白表达的影响[J].中国实验方剂学杂志,2010,16(02):84-86.

SHEN Ye-hua~1, FU Jie~1, LIU Lu-ming~. Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(2): 84-86.
[1]沈晔华,傅洁,刘鲁明,沈瑾,李栋良.清胰化积方联合吉西他滨对人胰腺癌SW1990移植瘤细胞凋亡及Bcl-2蛋白表达的影响[J].中国实验方剂学杂志,2010,16(02):84-86. DOI： 10.13422/j.cnki.syfjx.2010.02.047.

SHEN Ye-hua~1, FU Jie~1, LIU Lu-ming~. Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(2): 84-86. DOI： 10.13422/j.cnki.syfjx.2010.02.047.

摘要

目的:研究中药清胰化积复方联合化疗药物吉西他滨对人胰腺癌细胞SW 1990凋亡及Bc l-2蛋白表达的影响。方法:将荷SW 1990裸小鼠随机分为模型组、化疗组、化疗联合中药高、中、低剂量组

计算各组治疗后抑瘤率

并采用流式细胞术检测药物作用后肿瘤细胞的凋亡率

采用免疫组化法检测各组Bc l-2蛋白的表达情况。结果:化疗联合中药各组的瘤重均小于化疗组

化疗联合中药中剂量组的肿瘤细胞凋亡率高于化疗组

Bc l-2蛋白表达程度下降

有显著性差异。结论:清胰化积复方与吉西他滨联合应用

对人胰腺癌细胞SW 1990体内生长具有协同抑制作用

下调Bc l-2蛋白的表达

促进细胞凋亡可能是其作用机理之一。

Abstract

Objective:To explore the effect of the herbal decoction Qingyi Huaji formula（QYHJ） combined with gemcitabine on apoptosis and expression of Bcl-2 protein of human pancreatic cancer SW1990 in vivo.Methods: Tumor-burdened nude mice were randomized into control group

Chemo group

groups of Chemo plus QYHJ at different doses.After treatment

inhibiting rates of tumor growth were calculated.Cell apoptosis of each group was extracted by flow cytometry（FCM）.Expression of Bcl-2 protein was learned by method of immunohistochemistry.Result: Tumor weight in the Chemo plus QYHJ groups at different doses was significantly lower than that in the Chemo group（P<0.05）.Compared to the Chemo group

cell apoptosis rate in the Chemo plus QYHJ groups at middle dose was higher（P<0.05）

while the expression of Bcl-2 was lower（P<0.05）.Conclusion: QYHJ formula may have synergtic action on Gemcitabine

to inhibit the proliferation of human pancreatic cancer SW1990 in vivo

possibly by inhibiting expression of Bcl-2 protein and inducing cell apoptosis.

关键词

Keywords

references

Views

272

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 protein of Pancreastic Cancer SW1990 in Vivo

Effects of Capsaicin on Pancreatic Cancer SW1990 Cells

Effect of Qingyi Huaji Formula on Serum Immunosuppressive Factors and Immune Function of Splenic Lymphocytes in Mice with Pancreatic Cancer

Treatment of Sepsis-induced Inflammatory Responses with Xijiao Dihuangtang by Modulation of PKM2-mediated One-carbon Metabolism Pathway

Related Author

SHEN Ye-hua

FU Jie

LIU Lu-ming

SHEN Jin

LI Dong-liang

ZHANG Jian-jun

Chen Zhen

SHI Wei-dong

Related Institution

Cancer Hospital of Fudan University

Department of Oncology of Shanghai Medical College, Fudan University

上海200032

Affiliated Hospital of Nanjing University of Chinese Medicine

The First Clinical Medical College，Nanjing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰